Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Register for the Oligonucleotide Therapeutics and Delivery Conference

Celebrations for ASMD community as EU clears Sanofi’s Xenpozyme

Astellas pumps $90m into Sutro immuno-oncology alliance

Basilea preps key US filing for MRSA antibiotic ceftobiprole

Sanofi extends Health2Sync digital diabetes partnership to Japan

Strensiq

Strensiq

News/ Pharma Market Access/ Rare diseases/ UK & Europe

Alexion lambasts NICE over rare disease ruling

Andrew McConaghie Alexion, Highly Specialised Technology appraisals, NHS England, NICE, Rare diseases, Strensiq 0 Comment

Watchdog accused of ignoring stakeholder consensus and call for negotiations

X

Alexion lambasts NICE over rare disease ruling

https://pharmaphorum.com/news/alexion-lambasts-nice-over-rare-disease-ruling/

NICE1

Rare disease drug Strensiq too expensive, says NICE

Andrew McConaghie Alexion, NICE, Strensiq, Vimizim 0 Comment

Alexion’s new rare disease treatment Strensiq has been rejected by England’s health watchdog NICE in draft guidance. Strensiq

X

Rare disease drug Strensiq too expensive, says NICE

https://pharmaphorum.com/news/rare-disease-drug-strensiq-too-expensive-says-nice/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Ipsen beefs up in oncology, buying US biopharma Epizyme
GSK hepatitis B hope bepirovirsen heads for phase 3 test
Another Astellas gene therapy hits a safety hurdle
BioMarin gene therapy for haemophilia on course for EU approval
Study exposes lack of diversity in US cancer trials

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com